Andere Sprachen Destiny Pharma plc

Aktien

A2DW69

GB00BDHSP575

DEST

Verzögert London S.E. Andere Börsenplätze 11:53:44 14.06.2024			% 5 Tage	% 1. Jan.
11 ^GBX	+4,76 %		-30,16 %	-84,29 %

12.06.	GEWINNE UND HANDEL: Intuitive Investments NAV steigt, spricht über Hui10	AN
11.06.	ERGEBNISSE UND HANDEL: Chariot Verlust verringert sich; Destiny Pharma Zulassung	AN

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Destiny Pharma : Result of 2024 Annual General Meeting	13.06.
EARNINGS AND TRADING: Intuitive Investments NAV rises, talks up Hui10	12.06.
EARNINGS AND TRADING: Chariot loss narrows; Destiny Pharma approval	11.06.
Destiny Pharma Wins UK Regulator's Innovation Passport Tag for Nasal Drug Candidate	11.06.
Destiny Pharma plc Receives Innovation Passport Designation by the UK MHRA for XF-73 Nasal for the Prevention of Post-Surgical Site Infections	11.06.
Destiny Pharma : Notice of 2024 Annual General Meeting	09.05.
Norcros sells Johnson Tiles UK; Trifast trading well	25.04.
AIM WINNERS & LOSERS: Kromek jumps 14% on US government contract	25.04.
Destiny Pharma plc Reports Earnings Results for the Full Year Ended December 31, 2023	25.04.
EARNINGS AND TRADING: STV raises holding in Two Cities Television	31.01.
Destiny Pharma to Advance Skin, Colon Infection Therapies After Positive Evaluations	31.01.
Destiny Pharma plc Announces Clinical Development Update Positive Results from XF-73 Dermal Safety Study	31.01.
Destiny Pharma seeks to capitalise on XF-73 market potential in 2024	04.01.
Destiny Pharma Says Talks Ongoing with Potential Partners for Nasal Asset	04.01.
Destiny Pharma celebrates study findings on "potent" flagship drug	17.10.23
AIM WINNERS & LOSERS: Destiny Pharma posts "landmark" XF-73 data	17.10.23
Destiny Pharma plc Announces the Publication of New Microbiological Data on Xf-73 (Exeporfinium Chloride), Its Leading Antibacterial Drug,In Frontiers in Cellular and Infection Microbiology	17.10.23
Dianomi swings to loss; Epwin revenue up	20.09.23
Destiny Pharma : Interim results for the six months ended 30 June 2023	20.09.23
Earnings Flash (DEST.L) DESTINY PHARMA Reports H1 Loss GBX-3.10	20.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Destiny Pharma plc

Aktien

A2DW69

GB00BDHSP575

DEST

Andere Sprachen

Filter